Our Research Program

S&PAA’s research program, launched in 2020, is designed to complement early-stage and clinical research into schizophrenia’s origins, diagnosis and treatment by delivering insights on the personal and societal impact of schizophrenia. We have conducted the following research to date:

We also are involved in national efforts to accelerate treatment development and improve outcomes:

We fund and participate in the National Institutes of Health’s Accelerating Medicines Partnership-Schizophrenia (AMP-SCZ) Steering Committee. AMP-SCZ is working to improve schizophrenia treatments and treatment outcomes by identifying early indicators of the severe brain disease.

We fund and participate in the Biomarkers Consortium, led by the Foundation for the National Institutes of Health. Their mission is to create and lead cross-sector efforts that validate and qualify biomarkers and other drug development tools to accelerate better decision making for the development of new therapeutics and health technologies.

Only with more comprehensive, accurate data and analysis can the U.S. develop targeted policies and ultimately a better, more equitable system of care for people living with schizophrenia.

We welcome partnership to solve this societal issue. Contact us if you are interested in a research collaboration.